Department of Neurosurgery, School of Medicine, Emory University, 1365 Clifton Road Northeast, Bldg. B, Fl 2, Ste 2200, Atlanta, GA, 30322, USA.
J Neurooncol. 2022 Jun;158(2):133-137. doi: 10.1007/s11060-021-03850-3. Epub 2021 Oct 25.
The management of glioblastoma at the time of progression is an important facet of all physicians involved in neuro-oncology. This is an update of the evidence-based guidelines for management of progressive glioblastoma published by the Congress of Neurological Surgeons and American Association of Neurological Surgeons in 2014.
The medical literature from July 1, 2012 through March 31, 2019 was searched in MEDLINE® and Embase® and the Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Registry, and Cochrane Database of Abstracts of Reviews of Effects to determine if information was available to update, modify or create new recommendations related to imaging, cytoreductive surgery, neuropathology, radiotherapy, cytotoxic chemotherapy, targeted therapy, and immunotherapy.
The writing group utilized the information from the updated literature search to formulate recommendations that were exclusively evidence based and not founded on potentially biased consensus or expert opinion.
The series of guideline documents provides an update of the information and recommendations that could be derived in the 2014 version. It sets a benchmark as to what we really know about the management of this difficult disease. It also provides clues to key investigations that are necessary to move us toward truly effective disease control.
在进展期时对胶质母细胞瘤的治疗是所有神经肿瘤医生的重要关注点。这是对神经外科医师协会和美国神经外科医师协会在 2014 年发表的关于进展性胶质母细胞瘤治疗的循证指南的更新。
从 2012 年 7 月 1 日到 2019 年 3 月 31 日，在 MEDLINE® 和 Embase® 以及 Cochrane 系统评价数据库、 Cochrane 对照试验登记处和 Cochrane 疗效评价文摘数据库中检索医学文献，以确定是否有信息可以更新、修改或制定与影像学、细胞减灭术、神经病理学、放射治疗、细胞毒性化疗、靶向治疗和免疫治疗相关的新建议。
写作小组利用从更新的文献检索中获得的信息，制定了完全基于证据的建议，而不是基于潜在有偏见的共识或专家意见。
这一系列指南文件提供了 2014 年版本中可以获得的信息和建议的更新。它为我们对这种难治性疾病的治疗方法提供了一个基准。它还为我们提供了一些线索，这些线索指向了我们需要进行的关键研究，以实现真正有效的疾病控制。
